Aperiam Bio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Aperiam Bio is a private, preclinical-stage biotech founded in 2021, leveraging a novel AI/computer vision platform for protein engineering. The company emerged from stealth with $9 million in funding and holds a patent for its core technology. Its business model is a hybrid platform/partnership approach, delivering enhanced proteins for partners in cosmetics, technical reagents, and therapeutics, with an initial focus on pulmonary biologics.

Pulmonary

Technology Platform

Proprietary computer vision algorithms trained on 3D protein structures to identify local chemical misfits and recommend stabilizing mutations, leading to 'hyperfolding' variants with improved expression, solubility, and activity.

Opportunities

The platform addresses a universal bottleneck in biologics—protein stability—creating opportunities across cosmetics, industrial enzymes, and therapeutics.

The specific application to pulmonary delivery tackles a high-value unmet need in drug development, potentially enabling a new class of inhaled biologics.

Risk Factors

Key risks include the need for broader validation of the platform beyond model proteins, the challenge of securing and executing on major partnerships in a competitive field, and the scientific risk of competing against larger, well-funded AI protein design companies.

Competitive Landscape

Aperiam competes in the computational protein design space against AI-native biotechs (e.g., Generate Biomedicines, Isomorphic Labs) and established protein engineering firms. Its differentiation lies in its specific computer vision approach and its focused application to solving stability issues for nebulization and shelf-life.

More companies in Proteomics & Protein Engineering →More companies in United States →